Recombinant protective antigen anthrax vaccine (SparVax) - PharmAthene

Drug Profile

Recombinant protective antigen anthrax vaccine (SparVax) - PharmAthene

Alternative Names: Recombinant PA anthrax vaccine - PharmAthene; rPA anthrax vaccine (SparVax) - PharmAthene; rPA vaccine containing alhydrogel - PharmAthene; Second-generation rPA vaccine - PharmAthene; SparVax; Thraxine

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Avecia
  • Developer PharmAthene
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Anthrax

Most Recent Events

  • 19 Jan 2017 PharmAthene plans a phase II trial for Anthrax in USA
  • 09 Sep 2014 Additional pharmacodynamics data from a preclinical trial in Anthrax presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC- 2014)
  • 04 Jun 2014 Pharmacodynamics data from a preclinical trial in Anthrax released by PharmAthene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top